BBB Management GmbH Campus Berlin-Buch
BBB Management GmbH Campus Berlin-Buch develops and operates Campus Berlin-Buch, the leading location for biotechnology and biomedicine in the health region of Berlin. BBB stands for BiotechPark Berlin-Buch – the most important division of the company, which was founded in 1995, and is an integral part of the campus.
The main tasks of BBB GmbH are to aid biotechs – from start-ups to mature enterprises – in settling on campus and to provide them with assistance and support. An experienced and dedicated team is poised to provide flexible and individual services and solutions.
On behalf of the campus community, BBB GmbH operates a state-of-the-art, secure and efficient communication and information system with services and support, ensures comprehensive facility management and organizes and coordinates the technical operation of the campus infrastructure and maintenance of the green areas. The highly popular Life Science Learning Lab, which has a reputation throughout Germany as a life science education institution, promotes young talent, offers professional qualification courses as well as courses and activities for the general public.
Furthermore, BBB GmbH coordinates activities that affect the whole district of Buch. Within the framework of the Pankow District Alliance for Economic Affairs and Labor (BBWA), BBB GmbH is implementing the project “Development of the health region Berlin-Buch as an integral location for knowledge-based healthcare industry". The aim of this project, which started in 2011 and is scheduled to run through 2014, is to optimize the framework conditions of the health region Berlin-Buch and to develop it into a leading science, industry and health cluster within Berlin, underscoring the city’s focus on health. A further goal is to increase the attractiveness of the location for other companies.
As an economically independent, non-profit company with a public mandate, BBB GmbH is a neutral and intermediary partner. It uses the interfaces to research, clinical research, companies, administration, policy makers and the general public and participates in competence networks and support and service networks at regional and international levels.
The shareholders of BBB GmbH are the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) (60 %), the Leibniz-Institut für Molekulare Pharmakologie (FMP) (20 %) and Bayer HealthCare Pharmaceuticals, Bayer Pharma AG (20 %).